Back


11/09/2019
Ermium Therapeutics completes Series A funding of €6.3 million to develop breakthrough auto-immune therapeutics.
Ermium Therapeutics a Paris-based biotech company developing innovative health products for auto-immune and inflammatory diseases announced today a series A funding of €6.3 M with Domain Therapeutics, Kurma Partners, Idinvest, and the SATT Erganeo.

Download the pdf file





X

X